Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

被引:104
作者
Müller, U [1 ]
Hari, Y [1 ]
Berchtold, E [1 ]
机构
[1] Zieglerspital Bern, Div Med, CH-3007 Bern, Switzerland
关键词
immunotherapy; bee venom allergy; antihistamine premedication; terfenadine;
D O I
10.1067/mai.2001.111852
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Antihistamine premedication has been used to increase safety of specific-allergen immunotherapy, Its influence on the efficacy of this treatment has not been studied so far. Objective: The goal was to analyze the influence of antihistamine premedication on long-term efficacy of specific-allergen Immunotherapy. Method: Patients included in a double-blind, placebo-controlled trial who received premedication with terfenadine or placebo during initial rush Immunotherapy with honeybee venom in 1988/1989 were assessed in a retrospective analysis for the long-term protective effect, as indicated by the tolerance of a bce sting challenge or field sting during immunotherapy, Results: Of the 52 patients who had participated in the 1988/1989 trial, 47 could be reassessed after an average of 3 years. Of these, 45 were still receiving bee venom immunotherapy A total of 41 patients were stung by bees while receiving Immunotherapy (20 of the terfenadine-premedicated group and 21 of the placebo-premedicated group), 17 with in-field stings and 24 with in-hospital sting challenge. Six (29%) of the patients receiving placebo had a mild-to-moderate systemic allergic reaction, whereas none of the patients receiving terfenadine reacted to the bee sting (P =,012), Conclusions: These results indicate that antihistamine premedication during the initial phase of specific-allergen immunotherapy may enhance the efficacy of this treatment.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 26 条
[1]   Epitope-specific T cell tolerance to phospholipase A(2) in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro [J].
Akdis, CA ;
Akdis, M ;
Blesken, T ;
Wymann, D ;
Alkan, SS ;
Muller, U ;
Blaser, K .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1676-1683
[2]   Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects [J].
Bellinghausen, I ;
Metz, G ;
Enk, AH ;
Christmann, S ;
Knop, J ;
Saloga, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (05) :1131-1139
[3]   REDUCTION OF SIDE-EFFECTS FROM RUSH-IMMUNOTHERAPY WITH HONEY-BEE VENOM BY PRETREATMENT WITH TERFENADINE [J].
BERCHTOLD, E ;
MAIBACH, R ;
MULLER, U .
CLINICAL AND EXPERIMENTAL ALLERGY, 1992, 22 (01) :59-65
[4]   Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial [J].
Brockow, K ;
Kiehn, M ;
Riethmuller, C ;
Vieluf, D ;
Berger, J ;
Ring, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (04) :458-463
[5]  
FALUS A, 1992, IMMUNOL TODAY, V13, P154
[6]   CLINICAL CORRELATION OF THE VENOM-SPECIFIC IGG ANTIBODY LEVEL DURING MAINTENANCE VENOM IMMUNOTHERAPY [J].
GOLDEN, DBK ;
LAWRENCE, ID ;
HAMILTON, RH ;
KAGEYSOBOTKA, A ;
VALENTINE, MD ;
LICHTENSTEIN, LM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 90 (03) :386-393
[7]  
Herman D., 1996, Allergy (Copenhagen), V51, P68
[8]   HETEROGENEOUS EFFECTS OF HISTAMINE ON PROLIFERATION OF LUNG-DERIVED AND BLOOD-DERIVED T-CELL CLONES FROM HEALTHY AND ASTHMATIC PERSONS [J].
HOL, BEA ;
KROUWELS, FH ;
BRUINIER, B ;
LUTTER, R ;
BAST, A ;
WIERENGA, EA ;
JANSEN, HM ;
OUT, TA .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 8 (06) :647-654
[9]  
JARISCH R, 1988, ARB P EHRLICH I BUND, V82, P163
[10]  
JUTEL M, 1995, J IMMUNOL, V154, P4187